Search research articles
Contact Us
Filters
Showing results (71-80 of 156) with videos related to
Page
of 16
Sort By:
Biotechnology Journal
|
January 22, 2009
Rapid prototyping of scaphoid and lunate bones
Shaun D Gittard, Roger J Narayan, Jason Lusk, et al.
Leukemia & Lymphoma
|
September 3, 2010
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol
Pierre Morel, Jean-Nicolas Munck, Bertrand Coiffier, et al.
Blood
|
August 17, 2012
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia
Benedicte Hivert, Claudine Caron, Stephanie Petit, et al.
Blood Advances
|
November 21, 2018
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia
Stephanie Guidez, Julien Labreuche, Elodie Drumez, et al.
Medicine and Science in Sports and Exercise
|
April 18, 2025
Acute Effects of Daily Life Spontaneous and Structured Physical Activity on Glycemia in Children with Type 1 Diabetes
Angéline Melin, Elodie Lespagnol, Sémah Tagougui, et al.
Hematological Oncology
|
April 6, 2022
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Julien Labreuche, Deborah Assouan, Eric Durot, et al.
Science Advances
|
February 14, 2024
Cooperative pro-tumorigenic adaptation to oncogenic RAS through epithelial-to-mesenchymal plasticity
Hadrien De Blander, Laurie Tonon, Frédérique Fauvet, et al.
Frontiers in Cell and Developmental Biology
|
August 30, 2021
Opposite Roles for ZEB1 and TMEJ in the Regulation of Breast Cancer Genome Stability
Mélanie K Prodhomme, Sarah Péricart, Roxane M Pommier, et al.
Seminars in Oncology
|
April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Robert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Leukemia Research
|
December 29, 2022
Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease
Delphine Lebon, Adèle Dujardin, Alexis Caulier, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 156) with videos related to
Sort By:
Page
of 16
Biotechnology Journal
|
January 22, 2009
Rapid prototyping of scaphoid and lunate bones
Shaun D Gittard, Roger J Narayan, Jason Lusk, et al.
Leukemia & Lymphoma
|
September 3, 2010
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol
Pierre Morel, Jean-Nicolas Munck, Bertrand Coiffier, et al.
Blood
|
August 17, 2012
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia
Benedicte Hivert, Claudine Caron, Stephanie Petit, et al.
Blood Advances
|
November 21, 2018
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia
Stephanie Guidez, Julien Labreuche, Elodie Drumez, et al.
Medicine and Science in Sports and Exercise
|
April 18, 2025
Acute Effects of Daily Life Spontaneous and Structured Physical Activity on Glycemia in Children with Type 1 Diabetes
Angéline Melin, Elodie Lespagnol, Sémah Tagougui, et al.
Hematological Oncology
|
April 6, 2022
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Julien Labreuche, Deborah Assouan, Eric Durot, et al.
Science Advances
|
February 14, 2024
Cooperative pro-tumorigenic adaptation to oncogenic RAS through epithelial-to-mesenchymal plasticity
Hadrien De Blander, Laurie Tonon, Frédérique Fauvet, et al.
Frontiers in Cell and Developmental Biology
|
August 30, 2021
Opposite Roles for ZEB1 and TMEJ in the Regulation of Breast Cancer Genome Stability
Mélanie K Prodhomme, Sarah Péricart, Roxane M Pommier, et al.
Seminars in Oncology
|
April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Robert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Leukemia Research
|
December 29, 2022
Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease
Delphine Lebon, Adèle Dujardin, Alexis Caulier, et al.
Page
of 16